Clinical trials
Metastatic Breast Cancer ( HER2 Negative) clinical trials
Below are recruiting metastatic breast cancer ( her2 negative) clinical trials, each written for real people, not researchers. We’re tracking 486 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05879926RecruitingPhase 3
Testing chemo after hormone therapy in premenopausal early breast cancer
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
Birmingham, AlabamaAges 18–60 - NCT07088263RecruitingPhase 3
Adaptive Chemotherapy for Advanced Breast Cancer
This trial tests a new approach to chemotherapy that adapts over time for people with advanced breast cancer that has not responded to first-line treatment. It is designed to personalize treatment based on how the cancer responds, potentially improving outcomes with fewer side effects.
Guangzhou, GuangdongAges 18–75 - NCT06618287RecruitingPhase 1/Phase 2
Testing BMS-986507 for advanced lung and breast cancers
This study tests a new drug called BMS-986507, given in different combinations, for people with advanced solid tumors (lung cancer or breast cancer that has spread). It looks at safety, how the drug works in the body, and if it helps shrink tumors.
Birmingham, AlabamaAges 18 years+ - NCT07084558Recruiting
Testing treatment guided by tumor DNA for hormone positive breast cancer
This trial tests whether using a blood test (circulating tumor DNA) can help guide chemo and hormone therapy for early-stage, hormone receptor positive and HER2 negative breast cancer. The goal is to tailor treatment to your tumor's response, potentially reducing unnecessary side effects.
Vienna, AustriaAges 18–100 - NCT07174336RecruitingPhase 3
Testing Tersolisib with other treatments for advanced breast cancer
This trial tests a new study drug called Tersolisib combined with other anti-cancer treatments for people with advanced breast cancer that has a specific gene change (PIK3CA). The goal is to see if the combination can help shrink or slow the cancer.
Anchorage, AlaskaAges 18 years+ - NCT05071105Recruiting
Short-course radiation for early breast cancer in older women
This study looks at a brief type of radiation called SBRT given soon after starting hormone therapy for certain early breast cancers in women age 75 and older. It may help treat the cancer locally while aiming to be easier to receive than longer radiation schedules.
Rome, RomeAges 75 years+ - NCT06789172RecruitingPhase 1
New drug OKN4395 with or without pembrolizumab for solid tumors
This trial tests a new oral drug called OKN4395, which targets a COX2-related immune pathway, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors. It may be an option if you have certain types of cancer that have stopped responding to other treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT06222957Recruiting
How HER2 affects brown fat in breast cancer patients
This study looks at how a protein called HER2 affects brown fat activity in women with breast cancer. Brown fat helps burn calories and may influence treatment outcomes. You will be assigned to one of two groups based on your cancer's HER2 status, and the study will measure how your brown fat responds to cold.
CopenhagenAges 18 years+ - NCT05673928RecruitingPhase 2
Tucatinib and T-DM1 for HER2-positive brain-metastasis tumors
This Phase 2 study tests tucatinib plus T-DM1 (ado-trastuzumab emtansine) in people with HER2-positive metastatic solid tumors that have spread to the brain. It aims to shrink brain and body tumors and help control cancer that is progressing in the brain.
Houston, TexasAges 18 years+ - NCT07817056Recruiting
Managing blood sugar side effects from inavolisib
This study looks at how to best manage high blood sugar, a common side effect of the drug inavolisib, in people with a certain type of breast cancer. It aims to help patients stay on their treatment and improve their quality of life.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06165900RecruitingPhase 2
Radiation plus immunotherapy and chemo before surgery for triple-negative breast cancer
This trial tests combining stereotactic radiation therapy with immunotherapy (adebrelimab) and chemotherapy (nab-paclitaxel and carboplatin) before surgery for early or locally advanced triple-negative breast cancer. The goal is to see if this combination improves treatment response.
Shenyang, LiaoningAges 18–75 - NCT06214598Recruiting
Anti-inflammatory diet for breast cancer patients on hormone therapy
This study tests whether a special anti-inflammatory diet can help reduce side effects in breast cancer survivors who are taking aromatase inhibitors after menopause. You would be randomly assigned to either follow the diet for 6 months or continue your usual diet, and your health will be monitored.
BelgradeAges 45–70 - NCT07243002Recruiting
Patient outcomes with ribociclib or abemaciclib for early breast cancer
This study looks at how women and men with stage II or III HR+ HER2- breast cancer do when they start treatment with ribociclib or abemaciclib (combined with hormone therapy) after surgery. Researchers want to understand real-world experiences and results.
LondonAges 18 years+ - NCT06607757RecruitingPhase 2
Capivasertib plus fulvestrant for high-risk lobular breast cancer
This trial tests adding capivasertib to fulvestrant for women with a certain type of breast cancer (invasive lobular carcinoma) that is hormone-receptor positive and has a high risk of coming back. The treatment is given before surgery to see if it works better than fulvestrant alone.
AugsburgAges 18 years+ - NCT06643585RecruitingPhase 3
Comparing T-DXd to standard therapy for molecular relapse in early breast cancer
This trial compares a new drug called Trastuzumab-Deruxtecan (T-DXd) to standard treatment for people with early breast cancer whose cancer has come back at a molecular level (detected by a blood test) but hasn't spread to other parts of the body. The goal is to see if T-DXd can prevent the cancer from returning.
UlmAges 18–75 - NCT06923527RecruitingPhase 2
Testing ctDNA to start elacestrant in early breast cancer
This trial tests whether the drug elacestrant can help prevent recurrence in people with a type of breast cancer (ER+/HER2-) who have finished hormone therapy and have signs of cancer DNA in their blood (ctDNA positive) but no visible spread on scans.
New Haven, ConnecticutAges 18 years+ - NCT06139107RecruitingPhase 1
Radiation and abemaciclib plus letrozole before breast cancer surgery
This trial combines a short course of radiation before surgery with two oral medications (abemaciclib and letrozole) to treat early-stage, hormone-sensitive breast cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
Belleville, New JerseyAges 60 years+ - NCT05293470Recruiting
Tracking the real-world effects of Piqray in Korea
This study monitors how well and how safely Piqray works for people in Korea in routine care. You may be invited if your breast cancer matches specific genetic and receptor test results and you are starting Piqray for the first time.
Cheonan Si, Chungcheongnam-doAges 18–100 - NCT04614194RecruitingPhase 2
Blood and tumor markers to test response to abemaciclib
This trial studies how the immune system and other body signals in blood and tumor tissue relate to how well abemaciclib works before breast cancer surgery. The goal is to learn who benefits most from this medicine and why.
Dallas, TexasAges 18 years+ - NCT05059444Recruiting
Blood test to catch cancer early after treatment
This study looks for signs of cancer left in the body after treatment using a simple blood test (called a liquid biopsy). It aims to see if the test can catch cancer that might come back earlier than regular scans.
Birmingham, AlabamaAges 18 years+ - NCT05786716RecruitingPhase 2/Phase 3
Trastuzumab plus pertuzumab for HER2-mutated cancers
This trial tests whether combining trastuzumab and pertuzumab can treat cancers that have HER2 amplification or an activating HER2 mutation. It looks at people ages 12 and older, and may include both children/teens and adults, using the study drug based on their HER2 test results.
BelfastAges 12 years+ - NCT07114601RecruitingPhase 1
Study of LY4257496 for people with GRPR-positive solid tumors
This trial tests a new drug, LY4257496, in people with certain types of cancer that have a protein called GRPR on their cells. The study aims to see if the drug can help shrink tumors or slow the cancer's growth.
Duarte, CaliforniaAges 18 years+ - NCT06221748RecruitingPhase 2/Phase 3
Study of DV with cadonilimab for HER2-positive stomach cancer
This trial tests a combination of two drugs (DV and cadonilimab) for people with HER2-positive stomach or gastroesophageal junction cancer that has grown after first treatment. It aims to see if this combo can help when standard options have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT06590506Recruiting
Wearable health tracking for advanced solid tumor treatment
This trial studies how using a wearable device and smartphone app can help monitor your health during your first cancer treatment for advanced solid tumors. You will receive a known therapy (not a placebo), and the research team will collect real-world data to improve care.
A Coruña, A Coruña/ GaliciaAges 18 years+
Hear when a new Metastatic Breast Cancer ( HER2 Negative) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic breast cancer ( her2 negative)?
- Yes. Clin2 currently lists 486 recruiting metastatic breast cancer ( her2 negative) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic breast cancer ( her2 negative) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic breast cancer ( her2 negative) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- HER2-negative Breast Cancer
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Metastatic Triple-negative Breast Cancer
- HER2-positive Metastatic Breast Cancer
- Metastatic HER2-Negative Breast Carcinoma
- HR-positive, HER2-negative Advanced Breast Cancer
- Hormone Receptor Positive / HER2-negative Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.